- Yves Joanette PhD, FCAHSWDC Chair
Dr. Yves Joanette is Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Ageing. Dr. Joanette is also a Professor of Cognitive Neurosciences and Ageing for the Faculty of Medicine at the Université de Montréal. Dr. Joanette acts as the lead of the CIHR National Dementia Research Strategy, and as co-lead of other CIHR initiatives on eHealth and on Healthy and Productive Work.
Dr. Joanette sits on many international advisory and management boards, including several European initiatives in which Canada participates, including the EU Joint Programme on Neurodegenerative Disease Research. He is a member of the Steering Committee of the Joint Programming Initiative: More Years, Better Lives; of the Advisory Board of the Milken Institute’s Centre for the Future of Ageing; and of the Global Council on Brain Health.
- Raj LongWDC Vice-Chair
Raj Long is a senior executive with over 20 years’ experience in the pharmaceutical industry, including in senior regulatory roles at GE Healthcare MDx, Novartis and Bristol-Myers Squibb. She has also held various positions in industry expert groups and was responsible for setting up strategic organisations in Asia, Latin America, the Middle East and Africa, with a focus on shaping drug development strategy.
Raj Long is currently Deputy Director with the Bill and Melinda Gates Foundation, where she is the Pharmacovigilance Surveillance lead and has responsibility for programme strategies in malaria and neglected tropical diseases. She serves as an expert to the EC Innovative Medicines Initiative 2 Joint Undertaking by the European Commission; to the Innovative Medicines and Medtech Review Advisory Group; and to the Dutch Government, as part of the EU Presidency, in evaluating accelerated access and incentivised pricing models for the EU. In 2017, she was invited by the OECD, following a request by the G20 Presidency, to review access in high and low income countries. She is also a member of the NICE EXAG ROADMAP Expert Advisory Group.
- Professor Ricardo F. Allegri, MD, PhDWDC Member
Professor Ricardo F. Allegri is Head of the Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology and Director of the Ageing and Memory Centre at the Neurological Research Institute Raúl Carrea (FLENI) in Buenos Aires. He is also Professor of Neurology in the School of Medicine at the University of Buenos Aires and is chair of the Scientific Council at the Association against Alzheimer's disease and related disorders in Argentina (ALMA).
Professor Allegri has published extensively on cognitive neurology in neurological journals and books and has co-edited seven books, including, “Dementia: A Multidisciplinary Approach,” one of the most important books written in Spanish on this topic. He has received over 45 awards in the field of Cognitive Neurology and Neuropsychiatry, including the National Academy of Medicine Award in 2006 and the Research Recognition Award by the School of Medicine, University of Buenos Aires in 2014.
- Professor Philippe Amouyel, MD, PhDWDC Member and Global Team Lead
Professor Philippe Amouyel is General Director of Fondation Plan Alzheimer and Professor of Epidemiology and Public Health at the University Hospital of Lille, France. Since 1998, Professor Amouyel has headed a research unit of 50 people dedicated to public health and the molecular epidemiology of age-related diseases. He has published more than 750 scientific articles and participated in the discovery of 20 confirmed genetic loci predisposing to sporadic Alzheimer’s disease.
At the European level, Professor Amouyel also chairs the European Joint Programming Initiative on research on neurodegenerative diseases and Alzheimer’s in particular (JPND). The main objective of JPND is to combine the strength of European and global research to tackle these diseases more efficiently.
- Phyllis Barkman FerrellWDC Member
Phyllis Barkman Ferrell is the Vice President of the global Alzheimer’s team for Eli Lilly and Company. She and her team are responsible for the late-stage development and global registration of several treatments targeted for patients with Alzheimer’s disease. She has been with Eli Lilly for more than 20 years and has held many leadership roles throughout the organisation. She has led efforts in sales, marketing, alliance management, strategy, Six Sigma and corporate financial planning. She is also a member of the Indiana Chapter of the Healthcare Businesswomen’s Association and was recognised with their Rising Star Award in 2014. She is on the Boards of Directors for the Indiana Chapter of the Alzheimer’s Association and the Stanford Associate Board of Governors; and is a founding member of Women Against Alzheimer’s.
- Samantha Budd Haeberlein, PhDWDC Member
Dr. Samantha Budd Haeberlein is Vice President and Head of Alzheimer’s Clinical Development at Biogen and leads the team accountable for Global Clinical Development for their Alzheimer’s disease portfolio. She has over seventeen years of pharmaceutical industry experience across research, translational science/medicine and clinical development and is recognised internationally for leadership in Alzheimer’s disease drug discovery, diagnostics and clinical development. She is currently on the Board for The Boston Home, a residence and centre for the care of adults with advanced, progressive neurological diseases and has previously served on the Board for Rodin Therapeutics and the Stockholm Brain Institute. She previously worked at AstraZeneca in the US, Canada and Sweden, where she held a number of senior research and development roles in connection with Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.
- Hilary DoxfordWDC Member
Hilary Doxford is a former Vice Chair of Alzheimer’s Europe and is also an Alzheimer’s Society Ambassador, speaking nationally and internationally as a person with dementia. She was diagnosed with early onset Alzheimer’s disease at the age of 53.
Hilary Doxford also volunteers for the Alzheimer’s Society in England as part of their research network and user involvement programme; is a champion for “Join Dementia Research;” and is a member of Dementia Alliance International. She is a founder member of the UK Three Nations Dementia Working Group, established in 2017 to advocate for people with dementia and to collaborate with professionals working in the field.
- Kiki EdwardsWDC Member
Chief Kikelomo (Kiki) Laniyonu Edwards has over 30 years' experience in elder care provision and management. She is ADI Ambassador for the WHO African Region; the founder and chair of the Dementia Care Society of Nigeria (DCSoN); the founder and director of Rossetti Care Ltd, Nigeria; and has also established DementiaNigeria.com to raise awareness, educate and support families of Nigerians living with dementia.
Kiki Edwards has built a care centre and residential care facility in Nigeria and developed a network of Purple Angels and Dementia Champions to raise dementia awareness across Nigeria. She launched Purple Angel Dementia Awareness Nigeria in 2014 and Dementia Friends Nigeria in 2016. She has also educated communities on issues related to dementia; invited community members to participate in support groups, memory cafes, memory clinics, open days, and conferences; and fostered key alliances and engaged government officials in debates regarding policy on ageing.
- Margaret A. Hamburg, MDWDC Member
Dr. Margaret (Peggy) A. Hamburg is an internationally recognised leader in public health and medicine. She is the former Commissioner of the US Food and Drug Administration (FDA), having stepped down from that role in April 2015 after almost six years of service.
Peggy Hamburg is President-elect of the American Association for the Advancement of Science and is an elected member of the Council on Foreign Relations and the National Academy of Sciences, where she serves as Foreign Secretary. She currently sits on the board of the Commonwealth Fund, the Simons Foundation, the Urban Institute and the American Museum of Natural History. She is also a member of the Harvard University Global Advisory Council and the Scientific Advisory Committee for the Bill and Melinda Gates Foundation.
- Paul HoganWDC Member
Paul Hogan founded Home Instead Senior Care® with his wife Lori in 1994. Today, the franchise network is the world's leading provider of home care services for seniors, with more than 1,100 independently owned and operated offices that provide more than 60 million hours of care annually across 12 countries on four continents. In addition to his work with the World Dementia Council, Hogan serves on the Board of Governors for the Global Health and Healthcare Partnership Community at the World Economic Forum (WEF) and had previously served as the Vice Chair for the Global Agenda Council on Ageing.
- Jeremy HughesWDC Member and Trustee
Jeremy Hughes is Chief Executive of the Alzheimer’s Society in the UK, where he is leading the charity in its five-year strategy “The New Deal on Dementia 2017-22” and manages an annual budget in excess of £100m. Jeremy co-chairs the Dementia Friendly Communities Champions Group with top broadcaster Angela Rippon for the UK Prime Minister.
Jeremy is currently the co-chair of the UK Dementia Action Alliance and chair of the Global Alzheimer’s and Dementias Action Alliance. He was awarded the CBE for services to older people in the Queen's Birthday Honours 2015.
- Harry JohnsWDC Member and Global Team Lead
Harry Johns is CEO of the Alzheimer’s Association, which provides information and support to forty million people annually; has advanced public policy to improve care and dramatically increase U.S. federal research investments; and has been recognised as the worldwide non-profit leader in Alzheimer’s research impact.
- Kiyoshi Kurokawa, MD, PhDWDC Member
Dr. Kiyoshi Kurokawa is Chair, Health and Global Policy Institute; Professor, Emeritus of the University of Tokyo and National Graduate Institute for Policy Studies; Distinguished Research Affiliate, The MIT Media Lab; and Chair and Representative Director, Global Health Innovative Technology Fund.
Dr. Kurokawa is well known internationally in the fields of medicine, health, science, technology and innovation policies through his leadership, including as President of the Science Council of Japan and Science Adviser to the Prime Minister and WHO Commissioner. He was professor at UCLA School of Medicine, Tokyo University and Dean of Tokai University School of Medicine. He has received many awards, including the AAAS Scientific Freedom and Responsibility award and a 100 Top Global Thinkers award for his leadership in the National Diet of Japan Fukushima Nuclear Accident Independent Investigation Commission.
- Chris LlewellynWDC Member and Global Team Lead
Chris Llewellyn is a Partner in McKinsey and Company, based in London. A surgeon by background, he has extensive knowledge and experience in healthcare. He is the Head of McKinsey’s Medical Products practice in EMEA and a leader in their Life Sciences research and development practice.
Chris Llewellyn has worked with the President of Israel to plan a world-leading neurotechnology cluster and helped the then UK Prime Minister, David Cameron to develop a national life sciences strategy focusing on attracting investment and boosting employment in the sector and beyond.
- Tetsu Maruyama, MD, PhDWDC Member
Dr. Tetsu Maruyama is the Chief Scientific Officer at the Dementia Discovery Fund (DDF). His background is in neuroscience, working in academia and then in industry, where he was at Merck Sharpe and Dohme’s Neuroscience Research Centre in the UK and then at GSK, where he was the Director of the GSK Centre for Cognitive and Neurodegenerative Disorders in Singapore. In 2006, he moved to Takeda Pharmaceutical Company in Japan, as Head of CNS Research and then as Head of Global Drug Discovery, a position he held until his appointment to the DDF in April 2016.
- Professor Pierluigi Nicotera, PhDWDC Member
Professor Pierluigi Nicotera is Scientific Director and Chairman of the Executive Board of the German Center for Neurodegenerative Diseases, known as DZNE. He previously headed the Molecular Toxicology division at the University of Konstanz before becoming Director of the UK Medical Research Council Toxicology Unit.
Professor Nicotera is a renowned scientist and leading international expert in the field of neuronal cell death. Loss of neuronal synaptic connections and apoptosis play central roles in neurodegenerative diseases and his research has focussed on the molecular mechanisms that lead to neuronal demise following chronic and acute insults.
- Meera PattabiramanWDC Member and Trustee
Meera Pattabiraman is Chair of the Alzheimer’s and Related Disorders Society of India (ARDSI). She has been working in the field of dementia care, management and advocacy for the past 18 years. A post graduate in business administration, she entered the field of social work and dementia care because of her personal experience of being a carer for her father who had Alzheimer’s disease.
Meera Pattabiraman was part of the editorial board that produced the India Dementia Report in 2010, which is now used by the Ministry of Health and the Ministry of Social Justice and Empowerment as the reference guide in all matters relating to dementia. She is also part of the national think tank to develop better healthcare for the elderly and has taken part in national health policy meetings.
- Ronald C. Petersen, MD, PhDWDC Member and Global Team Lead
Dr. Ronald Petersen is director of the Mayo Clinic Alzheimer’s Disease Research Center and the Mayo Clinic Study of Ageing. He is also on the Board of Directors of the Alzheimer’s Association and is Chair of the Advisory Council on Research, Care and Services for the National Alzheimer’s Project Act.
Dr. Peterson has authored over 800 peer-reviewed articles and edited five books on memory disorders, ageing and Alzheimer’s disease. He has also received numerous awards for his work in medical research into Alzheimer’s disease and related disorders.
- Lisa RomettyWDC Member
Lisa Rometty is Vice President, Global Markets of the IBM Watson Health leadership team. With 25 years of strong leadership experience, she has global responsibility for all go-to-market strategy, marketing/public relations, business development, strategic partnerships and client engagement.
Lisa Rometty joined IBM from Baxter Healthcare, where she served in multiple executive positions during her 9-year tenure. Her most recent role was Global Franchise Head, Hospital Products, a $2.4 billion infusion therapy business that operated in over 70 countries and included a broad portfolio of products including infusion pumps, administration set and IV solutions. She also served as Vice President, Global Home Therapies leading all strategic marketing, new product development and commercialization for Baxter’s $4B Renal division. Prior to joining Baxter, she served in a variety of roles with increasing responsibility at GE Commercial and Consumer Finance for over 15 years.
- Kusumadewi (DY) SuharyaWDC Member
Kusumadewi (DY) Suharya is the Alzheimer's Disease International Regional Director, Asia Pacific and Founder of Alzheimer Indonesia, a NGO that works towards greater dementia awareness and risk reduction in Indonesia.
DY Suharya has 20 years’ experience in public health, public private partnerships and communication, as well as personal experience of dementia in caring for her mother. She also works closely with the World Health Organization and Indonesia’s Ministry of Health and has facilitated a working group at the Non-Communicable Disease Alliance regional meeting in New Delhi, India.
- Kate SwafferWDC Member
Kate Swaffer is CEO, Chair and co-founder of Dementia Alliance International; a PhD student; an Honorary Associate Fellow with the Faculty of Science, Medicine and Health at the University of Wollongong Australia; a board member and South East Asia Regional Ambassador of Alzheimer’s Disease International (ADI); and an international speaker. She is also the South Australian 2017 Australian of the Year; an author; an advocate for people with dementia; and is living beyond a diagnosis of younger-onset dementia.
- Li-Yu TangWDC Member
Li-Yu Tang is Secretary General of the Taiwan Alzheimer’s Disease Association (TADA), which she founded, and is a member of the Long-Term Care Committee of the Executive Yuan of Taiwan. She has over 25 years’ experience in dementia research, practice and training.
While at TADA, Li-Yu Tang has set up a toll-free helpline service, caregiver support groups and training programmes and a national dementia social support centre. She has created health promotion programmes for people with dementia and their care givers and provided training and coaching to more than sixty organisations throughout the country to help them deliver the programmes. She is also a consultant to Taipei City Government and is a member of a long-term care committee of four city governments in Taiwan.
- George VradenburgWDC Member and Trustee
George Vradenburg convenes the Global CEO of Initiative on Alzheimer’s (CEOi), a patient-centered industry coalition working with government, researchers and patients to develop and deliver innovative medicines to those touched by dementia and improve their quality of care. He also chairs the Global Alzheimer's Platform Foundation (GAP) and is chair and co-founder of USAgainstAlzheimer’s (USA2), which convenes CEOi and is a “disruptive,” entrepreneurial and patient-focused US based NGO committed to stopping Alzheimer’s disease by 2020.
USA2 also founded and leads GAP, the North American arm of a global initiative to re-engineer Alzheimer's clinical trials for greater speed, efficiency, quality and diversity; and co-convenes Leaders Engaged on Alzheimer’s Disease, a US-based 90+ member coalition of Alzheimer’s-serving organisations mobilising a movement to end Alzheimer's. George Vradenburg is also a member of the Council on Foreign Relations and the Economic Club of Washington, DC. Before his retirement, he served in senior executive positions at AOL/Time Warner, Fox and CBS.
The World Dementia Council (WDC) has 24 members working across six continents. WDC’s members attend WDC meetings, vote on key issues and chair or participate in WDC’s global teams. We currently have one vacancy for a member.